Daptomycin is an option for treating endovascular infection due to MRSA. The drug is inactivated by surfactant, so it should not be used to treat pneumonia.
Tigecycline can cause permanent tooth discoloration and should not be used in young children and pregnant women.
RAM-POSITIVE BACTERIA have become common causes of hospital-acquired infections. Friedman et al, 1 in a study of 361 patients with nosocomial bloodstream infections, found that the top three organisms were Staphylococcus aureus, S epidermidis, and enterococcal species. 1 At the same time, antibiotic resistance is on the rise, often leaving few therapeutic options. 1, 2 Resistance is even being seen in community-acquired infections: methicillinresistant S aureus (MRSA) infections are now also found in people who have not recently received health care. 3 Although vancomycin remains effective, several new antibiotics have become available to assist in the management of serious grampositive infections. This article uses two case scenarios to discuss when and how to use these agents and how to monitor for and respond to their adverse effects. large vegetation on the tricuspid valve. Synovial fluid aspirated from her left knee has a white blood cell count of 66 × 10 9 /L. Cultures of her blood and synovial fluid grow MRSA.
The patient is treated with vancomycin and gentamicin. She improves but requires open-heart surgery because of severe tricuspid insufficiency.
■ VANCOMYCIN SHOULD BE USED JUDICIOUSLY
Discovered in 1952, vancomycin is produced by the mold Streptomyces orientalis. 4 It was originally developed to combat penicillinresistant S aureus. However, it is active against most gram-positive aerobic and anaerobic organisms. It works by binding to D-alanyl-Dalanine peptide precursors in the bacterial cell wall, preventing the cross-linking of peptidoglycan side chains and therefore inhibiting cell-wall synthesis. It is bactericidal and may trigger cell autolysis. The use of vancomycin has increased significantly over the past 25 years, and it remains the workhorse agent for beta-lactamresistant staphylococcal and enterococcal infections in most hospitals. Its empiric use has also increased, owing to an increase in penicillin-resistant Streptococcus pneumoniae infections.
Although we rely on vancomycin for treating gram-positive infections, it should be used judiciously to forestall the further development and spread of vancomycin-resistant enterococci (VRE) and S aureus. 5 Vancomycin is not absorbed across the bowel wall and therefore it is limited to parenteral administration for all infections other than Clostridium difficile-associated diarrhea.
Dosage is based on body weight. Because it is eliminated almost exclusively by the kidneys, the dosage should be adjusted for patients with reduced creatinine clearance and can be calculated with the use of nomograms. 6 Although the need to routinely monitor blood levels of vancomycin is debatable, a target trough level of at least 15 µg/mL can help ensure that the dosage is adequate in patients with bacteremia, endocarditis, and hospital-acquired pneumonia. 7 The main adverse reaction to vancomycin is "red man syndrome," an infusion-related toxicity characterized by fevers, chills, and flushing of the upper trunk and face. Nephrotoxicity and ototoxicity sometimes occurred in the past, most likely because early preparations contained impurities. 6 Vancomycin still appears to potentiate aminoglycoside nephrotoxicity.
■ CASE 2: FEVER IN A LIVER TRANSPLANT RECIPIENT
A 8 Linezolid works by binding to a subunit (designated 23S) of the bacteria's ribosomal RNA, preventing the final ribosomal complex from forming and thereby blocking protein synthesis. It is bacteriostatic, kills in a timedependent fashion, and has a postantibiotic effect (ie, it continues to suppress bacterial growth even after the drug concentration in the blood falls to undetectable levels). 9 
Vancomycin remains the workhorse agent for resistant infections in most hospitals
Linezolid is 100% orally bioavailable and is metabolized in the liver to inactive byproducts. Although 30% to 40% of a dose is eliminated unchanged by the kidneys, no dosage adjustment is necessary for patients with renal impairment. 10 Adverse effects, drug interactions, resistance Treatment-limiting toxicities include myelosuppression, which manifests as thrombocytopenia and anemia. Peripheral and optic neuropathy may also occur. [11] [12] [13] Patients should have their blood monitored for cytopenias weekly, especially if they receive the drug for longer than 2 weeks.
Linezolid is a reversible, nonselective inhibitor of monoamine oxidase and may interact with adrenergic and serotonergic agents. A mild pressor effect has been observed in normotensive patients taking linezolid with pseudoephedrine but not with dextromethorphan. Patients taking linezolid with selective serotonin reuptake inhibitors should be closely observed for serotonin syndrome (ie, cognitive dysfunction, fever, incoordination). 10 When linezolid was first introduced, experts hoped that resistance would be slow to develop. Unfortunately, there are already reports of resistance in VRE and MRSA isolates in patients previously exposed to linezolid. Resistance is associated with mutations of the domain V region of 23S rRNA, where linezolid binds. 14 
■ CASE 2 CONTINUED: HER PLATELET COUNT DROPS
In the hospital, the patient's jaundice and malaise persist, although her fever abates and her blood pressure and other hemodynamic measures stabilize. At 3 weeks, her platelet count has dropped: on admission it was 95 × 10 9 /L, but now it is 19. An evaluation for reversible causes of thrombocytopenia does not reveal anything besides her liver dysfunction and line- 
■ QUINUPRISTIN-DALFOPRISTIN FOR SERIOUS VREF INFECTIONS
Quinupristin-dalfopristin consists of two streptogramins that inhibit protein synthesis by binding to the 50S subunit of the bacteria's ribosomes. 15 It is active against MRSA and vancomycin-resistant E faecium (VREF) but not against E faecalis. It is bactericidal against staphylococci and streptococci and is bacteriostatic for enterococcal species. Quinupristin-dalfopristin was granted accelerated approval by the FDA for the treatment of serious or life-threatening VREF infections. Its current indications are to treat adults with serious VREF infections associated with bacteremia and complicated skin infections and skin-structure infections due to group A streptococci or methicillin-susceptible S aureus. 15, 16 Myalgia, arthralgia, and drug interactions Up to 30% of patients who receive quinupristin-dalfopristin develop treatment-limiting myalgia and arthralgia 17 that are typically refractory to standard pain treatment, including opioids and nonsteroidals, but resolve when quinupristin-dalfopristin is stopped.
The clinical utility of quinupristin-dalfopristin is further limited by numerous drug interactions: the drug inhibits the cytochrome P450 3A4 isoenzyme and therefore can increase the serum levels of drugs that are metabolized by this enzyme, eg, astemizole, cisapride, cyclosporine, disopyramide, lidocaine, midazolam, nifedipine, quinidine, and terfenadine. 16 
■ CASE 2 CONTINUED: MYALGIA DEVELOPS
The patient remains afebrile on a regimen of amphotericin B lipid complex, ciprofloxacin, and quinupristin-dalfopristin. A small residual fluid collection remains in her liver. Her status on the liver transplantation list is upgraded to the highest priority (status 1A). However, the patient develops disabling myalgias. She cannot walk (even moving about in bed is painful), and she requires continuous opioid analgesia. Her physicians obtain approval for compassionate use of daptomycin (it is in phase 3 trials at the time of this case), her quinupristin-dalfopristin is stopped, and the myalgia abates. A donor liver becomes available, and it is successfully transplanted.
■ DAPTOMYCIN

Daptomycin was approved in September 2003
and is currently indicated for complicated skin and skin-structure infections caused by daptomycin-susceptible staphylococcal and streptococcal species, as well as vancomycin-susceptible E faecalis. 18 Studies in patients with bloodstream and endovascular infection due to S aureus are in progress. Daptomycin is inactivated by surfactant, so it is not appropriate for treating pneumonia.
Daptomycin was discovered in the 1980s, but its development was suspended because of skeletal muscle toxicity. This toxic effect was found to be due to high trough concentrations, so further investigations used a different dosing schedule.
Daptomycin is a cyclic lipopeptide that is active against gram-positive organisms only. It is thought to act by forming an ion conduction structure in the cytoplasmic membrane that dissipates the ion concentration gradient. 18 The pharmacodynamics depend on drug concentration, and there is a significant postantibiotic effect.
Side effects, drug interactions, and resistance
Patients receiving daptomycin should be monitored for skeletal myopathy by measuring their serum creatine phosphokinase levels every week. In addition, one should consider temporarily discontinuing agents that can cause rhabdomyolysis, such as statins.
Resistance to daptomycin has emerged in patients treated for bloodstream MRSA and VRE infections. 19, 20 The mechanism of resisUp to 30% of patients on quinupristindalfopristin develop treatmentlimiting myalgia and arthralgia tance has not yet been elucidated, and cut points for defining susceptibility and resistance have not been fully validated.
■ TIGECYCLINE: THE NEWEST AGENT
Tigecycline is the newest FDA-approved agent with activity against multidrug-resistant, gram-positive pathogens. It is the first available glycylcycline, a synthetic analogue of tetracycline that has similar antibacterial activity but circumvents the two major mechanisms of tetracycline resistance: efflux and ribosomal protection. 21 Tigecycline is effective against complicated skin and skin-structure infections and intra-abdominal infections. It is active against VRE strains and MRSA, as well as certain Enterobacteriaceae and anaerobes. 22 However, tigecycline has been shown to be affected by multidrug efflux pumps in gram-negative organisms, particularly Proteus mirabilis and Citrobacter freundii.
Adverse effects
The main adverse reactions are nausea and vomiting. As with tetracyclines, tigecycline may cause permanent tooth discoloration, so it should not be taken by young children or pregnant women.
Drug interactions have not been observed. Dosage should be adjusted for patients with hepatic insufficiency. 22 ■ THERAPEUTIC APPROACH Sensitive gram-positive infections: Use beta-lactam antibiotics Beta-lactam antibiotics are preferred for grampositive infections in which no resistant organisms are identified. If a broader-spectrum agent is used initially, it should later be changed to the agent with the narrowest spectrum indicated by susceptibility testing. For example, oxacillin or nafcillin should be used for methicillin-susceptible S aureus infections, and ampicillin should be used for sensitive enterococcal species.
Beta-lactam antibiotics are often avoided because a patient reports a history of penicillin allergy. But the validity of such a history is often difficult to confirm. Vancomycin use can be reduced by consistently performing penicillin skin testing in patients with suspected allergy: most patients with "penicillin allergy" can actually take a beta-lactam antibiotic safely. 23, 24 Resistant gram-positive infections: Start with vancomycin Serious infections due to beta-lactam resistant, gram-positive bacteria require a multifaceted therapeutic approach.
S aureus and enterococcal species tend to cause endovascular infections with subsequent metastatic foci. Therefore, patients with bacteremia due to these pathogensespecially those with prosthetic heart valves or cardiac devices-should be thoroughly evaluated for endocarditis. The use of central vascular catheters should be limited, and existing lines should be removed. Suppurative collections should be drained either surgically or percutaneously whenever possible.
Vancomycin is still the first-line therapy for hospitalized patients with beta-lactamresistant, glycopeptide-sensitive, gram-positive infections.
If an oral agent is needed
The emergence of community-acquired MRSA has affected the treatment of patients who present with a skin or skin-structure infection. Those patients who do not require hospital admission may need an oral antibiotic. Linezolid covers a very broad spectrum, but its high cost is often prohibitive. Doxycycline, clindamycin, and trimethoprim-sulfamethoxazole are possible choices for likely MRSA; however, soft-tissue infections can be caused by Streptococcus pyogenes, which trimethoprim-sulfamethoxazole does not reliably cover. To treat outpatient infections effectively, one should follow up with the patient closely, control the source of infection, and attempt to make a microbiological diagnosis.
Using new antibiotics
Therapy with antibiotics other than vancomycin must be individualized (as in the above case of the liver transplant recipient), preferably with the help of an infectious disease consultant.
Most 'penicillinallergic' patients are not
Daptomycin's bactericidal activity may make it a good choice for treating endovascular MRSA infections, but it is not an option for pneumonia. For treating VRE, there is more experience with linezolid than with daptomycin; as far as we know, no head-to-head clinical trials have compared the two. The use of quinupristin-dalfopristin is limited by its toxicity and infusion-associated vein irritation. Tigecycline's broad spectrum of activity provides the ability to use a single agent for complicated polymicrobial infections that include gram-positive infections.
Will new antibiotics supplant vancomycin for treating glycopeptide-sensitive gram-positive infections? Two clinical syndromes due to MRSA deserve mention:
Hospital-acquired pneumonia due to suspected MRSA. Recent consensus guidelines for treating hospital-acquired pneumonia recommend vancomycin or linezolid for empiric therapy if MRSA is suspected. 25 This recommendation is based in part on a retrospective subgroup analysis of two prospective clinical trials that actually showed linezolid to be associated with a higher survival rate than vancomycin in patients with nosocomial MRSA pneumonia. 26 Although this finding has not been prospectively confirmed, it raises the question of whether linezolid should be the first-line drug in hospitals in which nosocomial MRSA pneumonia is common.
Prolonged MRSA bacteremia. Although the evidence is mixed, some studies indicate that patients with MRSA bacteremia fare worse than those with methicillin-sensitive S aureus bacteremia. 27 A possible explanation is that vancomycin is not as effective as nafcillin or oxacillin. Alternatives to vancomycin might better treat MRSA, particularly for patients with endovascular infections.
■ FUTURE DIRECTIONS
Recent evidence shows that a polymorphism in the agrII operon of certain MRSA strains is associated with prolonged bacteremia. 28 This phenotype, characterized by decreased production of autolysin and increased cell surface virulence factors, may be the first step towards vancomycin-intermediate S aureus. 29 Further work in this area, along with the results of a trial of daptomycin for the treatment of S aureus bacteremia, may help guide treatment decisions in the future. recommend  vancomycin or  linezolid for  suspected  nosocomial  MRSA  pneumonia 
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